NDA 021632 · Vicuron Holdings
Eraxis
Anidulafungin · Intravenous · Echinocandin Antifungal
NovelLast checked: Nov 20, 2026Latest source record: Oct 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Feb 17, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
34
15 Phase 3, 0 recruiting
FAERS reports
1,627
1,582 serious, 692 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 19, 2025.
ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis in adults and pediatric patients 1 month of age and older [see Clinical Studies (14.1) and Microbiology (12.4) ] . 1.2 Esophageal Candidiasis ERAXIS is indicated for the treatment of esophageal candidiasis in adults [see Indications and Usage (1.3) , Clinical Studies (14.2) ] . 1.3 Limitations of Use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida , and has not been studied in sufficient numbers of neutropenic patients to determine efficacy in this group. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established [see Warning and Precautions (5.3) , Use in Specific Populations (8.4) ] . • ERAXIS is associated with high relapse rates in esophageal candidiasis [see Clinical Studies (14.2) ] . 1.4 Usage Specimens for...
Mechanism: Anidulafungin is an anti-fungal drug [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 22, 2020 Supplement 27 · Efficacy LetterLabel
- Feb 17, 2006 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
2 products under this application
- ERAXIS · ANIDULAFUNGIN 50MG/VIAL · POWDER, INTRAVENOUS · Prescription
- ERAXIS · ANIDULAFUNGIN 100MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Anidulafungin" as an intervention, any sponsor and status, largest first.
- Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive AspergillosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00531479 · 459 participants · Start Jul 2008 · Primary completion Apr 2011
Drug: voriconazole; anidulafungin and 1 more · For: Aspergillosis
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 107 sites in all
- Echinocandin Added to Standard Treatment for Severe Pneumocystis PneumoniaPivotal-lookingNot yet recruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT07900373 · 416 participants (planned) · Start Apr 1, 2027 · Primary completion Apr 1, 2032
Drug: Echinocandins; Placebo (0.9% Sodium chloride) infusion · For: Pneumocystis Jirovecii Pneumonia
Sites: Montreal, Canada
PfizerPfizer (PFE)
NCT00496197 · 282 participants · Start Jul 2007 · Primary completion Jun 2010
Drug: Eraxis (anidulafungin); Diflucan (fluconazole) and 1 more · For: Candidiasis
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 43 sites in all
- The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive CandidiasisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00056368 · 256 participants · Start Mar 2003
Drug: Anidulafungin; Fluconazole · For: Candidiasis
Sites: King of Prussia, Pennsylvania
- Anidulafungin Versus Fluconazole in the Treatment of CandidemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00058682 · 248 participants · Start Apr 2003
Drug: Anidulafungin · For: Candida; Candidiasis
Sites: Bethesda, Maryland
- Anidulafungin Candidemia/Invasive Candidiasis Intensive Care StudyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00689338 · 216 participants · Start Jul 2008 · Primary completion May 2010
Drug: Anidulafungin; Fluconazole and 1 more · For: Invasive Candidiasis
Sites: Vienna, Austria; Brussels, Belgium; Ghent, Belgium · 61 sites in all
- Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant RecipientsPivotal-lookingCompleted
University of PittsburghAcademic, hospital or other
NCT00841971 · 200 participants · Start Feb 2010 · Primary completion Jul 2013
Drug: Anidulafungin; Fluconazole · For: Mycoses; Fungemia; Central Nervous System Fungal Infections and 1 more
Sites: Los Angeles, California; Miami, Florida; Ann Arbor, Michigan · 6 sites in all
PfizerPfizer (PFE)
NCT00037219 · 120 participants · Start Aug 2001
Drug: Anidulafungin, VER002 · For: Candidiasis
Sites: King of Prussia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective393
- off label use187
- multiple organ dysfunction syndrome174
- septic shock128
- sepsis118
- pneumonia94
- candida infection92
- pyrexia92
- neutropenia85
- death80
- drug resistance72
- condition aggravated70
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 8 |
| 2007 | 18 |
| 2008 | 12 |
| 2009 | 24 |
| 2010 | 36 |
| 2011 | 47 |
| 2012 | 28 |
| 2013 | 24 |
| 2014 | 22 |
| 2015 | 21 |
| 2016 | 52 |
| 2017 | 70 |
| 2018 | 118 |
| 2019 | 122 |
| 2020 | 123 |
| 2021 | 138 |
| 2022 | 189 |
| 2023 | 174 |
| 2024 | 157 |
| 2025 | 145 |
| 2026 | 99 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Eraxis (Anidulafungin)
2024 spending
$483K
Beneficiaries
134
529 claims
Per beneficiary
$3,602
$92.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $590,076 |
| 2021 | $759,886 |
| 2022 | $475,972 |
| 2023 | $593,317 |
| 2024 | $482,685 |
Part B: Eraxis* (Anidulafungin*) · HCPCS J0348
2024 spending
$7K
Beneficiaries
11
128 claims
Per beneficiary
$599
2024 ASP limit $0.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,231 |
| 2021 | $9,647 |
| 2022 | $17,869 |
| 2023 | $7,547 |
| 2024 | $6,594 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combination antifungal therapy for invasive aspergillosis: a randomized trial.
Marr KA, Schlamm HT, Herbrecht R, et al. · Ann Intern Med 2015 · Multicenter Study, Randomized Controlled Trial
- Does Weight Impact Anidulafungin Pharmacokinetics?
Lempers VJ, van Rongen A, van Dongen EP, et al. · Clin Pharmacokinet 2016 · Clinical Trial, Phase IV
- Echinocandin use in lung transplant recipients.
Al Jishi Y, Rotstein C, Kumar D, et al. · Clin Transplant 2018 · Clinical Trial
- The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: A systematic review.
Jendoubi A, Pressiat C, De Roux Q, et al. · Int J Antimicrob Agents 2024 · Systematic Review
- Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis.
Cheng J, Han H, Kang W, et al. · Front Microbiol 2024 · Systematic Review
- Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2004 · Clinical Trial
Sponsor: Vicuron Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.